Premium
Pharmacokinetics, Bioequivalence, and Safety Studies of Prucalopride in Healthy Chinese Subjects
Author(s) -
Zhou Ziye,
Wang Chenxiang,
Zheng Xuyong,
Yu Xuben,
Yu Chao,
Zhang Dongchuan,
Xia Yan,
Chen Huafang,
Huang Xiaoxiao,
Zhang Xiuhua
Publication year - 2019
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.754
Subject(s) - bioequivalence , pharmacokinetics , medicine , adverse effect , dosing , crossover study , pharmacology , placebo , alternative medicine , pathology
Abstract The objectives of the present study were to evaluate the bioequivalence of 2 tablet formulations of prucalopride, generic and branded, and to investigate relevant pharmacokinetic and safety profiles. This study was designed as a randomized, open‐label, fasting, single‐dose, crossover, and dual‐period trial. After overnight fasting, 12 subjects were given prucalopride tablets via oral administration, and blood specimens were obtained up to 96 hours after dosing. Prucalopride concentrations in plasma were measured using ultraprecision liquid chromatography–tandem mass spectrometry followed by calculation of pharmacokinetic parameters. The safety of prucalopride was assessed throughout the study. The pharmacokinetics of prucalopride can be defined as a 2‐compartment model with a long elimination phase. No significant differences were observed between the pharmacokinetic profiles of the generic and branded prucalopride tablets. Bioequivalence was evaluated using 90%CIs for the ratio test/reference of log area under the concentration‐time curve over 96 hours, log area under the concentration‐time curve to infinity, and log peak concentration from generic and branded tablets, which were 100.06–109.94%, 100.63–110.32%, and 95.84–113.08%, respectively. During administration of the medication, there were 18 adverse events in 6 subjects in the test formulation group and 19 cases of adverse events in 6 subjects in the reference formulation group ( P > .05). No severe adverse effects were detected. These results suggest that generic and branded prucalopride tablets are bioequivalent and show similar safety profiles.